Press Room

2016 AIChE Annual Meeting

Start
Sunday, November 13, 2016 - 00:00
End
Friday, November 18, 2016 - 00:00
Location: San Francisco, United States
Cocrystals amorphous solid dispersions | Hovione

HOVIONE PRESENTATIONS

1. Multi-Scale Modeling in Pharmaceutical Drug Substance Manufacturing

José L.C. Santos, Rui C. Silva and Filipe A.P. Ataíde

Date: Monday, Nov 14

Presentation Time: 12:30 PM

Location: Continental 5 (Hilton San Francisco Union Square)

2. Evaporation of Binary Mixtures and Shell Formation in Spray Dried Droplets

Pedro Valente, Íris Duarte, Tiago Porfirio, Xu Liu, Feng Zhang and Márcio Temtem (in collaboration with University of Texas)

Session: Tools for Accelerating Pharma Development and Innovations in Biopharmaceutical Discovery, Development, and Manufacturing 

Date: Tuesday, Nov 15

Presentation Time: 1:58 PM - 2:20 PM 

Location: Continental 5 (Hilton San Francisco Union Square)

3. Evaluating Mixing Performance in a Stirred Tank Reactor with Different Impeller Geometries and Reactor Size By CFD

Rui C. Silva
, Filipe A.P. Ataíde and José L.C. Santos

Date: Wednesday, Nov 16

Presentation Time: 8:30 AM

Location: Union Square 1 & 2 (Hilton San Francisco Union Square)

4. Scale-up of Reaction and Crystallization Steps of a Commercial Manufacturing Process in a Multi-Purpose Plant Using Mechanistic Modeling 

Filipe A.P. Ataíde, Rui C. Silva and José L.C. Santos

Date: Thursday, Nov 17

Presentation Time: 10:15 AM

Location: Continental 4 (Hilton San Francisco Union Square)

5. Secondary Drying Scale-up Methodology: Eliminating a bottleneck with a Lean Development Approach

Tiago Porfirio, Pedro Valente, Ines Matos, Jorge Moreira, João Vicente, Márcio Temtem and Viriato Semião

Session: Quality By Design in Drug Product Formulation, Design, & Process Development I 

Date: Thursday, Nov 17

Presentation Time: 1:08 PM - 1:27 PM 

Location: Continental 4 (Hilton San Francisco Union Square)

 

HOVIONE POSTERS at POSTER SESSION

Date: Monday, November 14, 2016

Session Time: 3:15 PM - 5:45 PM

Location: Grand Ballroom B (Hilton San Francisco Union Square)

 

1. Modelling Approaches to Spray Drying Process Development, Scale-up and Troubleshooting

Pedro Valente, Íris Duarte, Filipe  Neves and Márcio Temtem

2. Predicting the In Vivo Performance of Amorphous Solid Dispersions Based on Molecular Descriptors and Statistical Analysis

Íris Duarte, João Henriques, João F. Pinto, Márcio Temtem

 

Contact us if you would like to schedule a meeting or to find more about the Hovione presentations at 2016 AIChE Annual Meeting.

Schedule a meeting button | Hovione

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026